FY2026 EPS Estimates for Ekso Bionics Cut by HC Wainwright

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of Ekso Bionics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.00 per share for the year, down from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ FY2027 earnings at $0.12 EPS and FY2029 earnings at $0.46 EPS.

A number of other equities analysts have also commented on EKSO. Lake Street Capital lowered their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday. StockNews.com assumed coverage on shares of Ekso Bionics in a report on Monday. They set a “hold” rating on the stock.

Ekso Bionics Stock Down 8.0 %

EKSO stock opened at $0.44 on Wednesday. Ekso Bionics has a fifty-two week low of $0.37 and a fifty-two week high of $1.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The stock has a market capitalization of $9.64 million, a price-to-earnings ratio of -0.67 and a beta of 1.46. The business’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.82.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The firm had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.